In summary, ERβ could promote ccRCC progression via altering the ANGPT-2/Tie-2 signaling-mediated angiogenesis and inhibiting the ERβ/ANGPT-2/Tie-2 signals with antiestrogen ICI182,780 may increase the sunitinib sensitivity to better suppress ccRCC progression (Fig. 8). Here, ESR2 is linked to nonpapillary renal cell carcinoma.